Can you buy $1 for 80 cents? Stock markets rarely provide the opportunity to invest in an asset that's worth than the net cash it carries on its books.
Keep Reading →
April 17 - Hedge Funds, News - Comments
The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources...
Keep Reading →
November 22 - Hedge Funds, News - Comments
With markets flat after the bell on Wednesday, investors are focused on individual stocks that are reporting their earnings for the previous quarter.
Keep Reading →
October 21 - Earnings Report, Market Movers, News - Comments
Synta Pharmaceuticals Corp.
Keep Reading →
September 11 - News - Comments
In the 21st century investor’s toolkit, there are many methods shareholders can use to track publicly traded companies.
Keep Reading →
September 9 - News - Comments
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference...
Keep Reading →
September 5 - News - Comments
In the 21st century investor’s toolkit, there are dozens of indicators market participants can use to watch the equity markets.
Keep Reading →
September 3 - News - Comments
If you were to ask many of your peers, hedge funds are assumed to be overrated, outdated financial vehicles of a forgotten age.
Keep Reading →
August 22 - News - Comments
While the major indexes pulled back this week, their declines paled in comparison to the huge drops experienced by a handful of health-care stocks.
Keep Reading →
August 19 - News - Comments
How would you like to make a 27%-plus return on your investment -- within one week? Shareholders in three health-care companies enjoyed such gains this week.
Keep Reading →
August 5 - News - Comments
With the SPDR S&P Biotech Index up 43% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
August 5 - News - Comments
With luck, Santa Clarita’s MannKind Corporation (NASDAQ:MNKD) hopes to have FDA approval by April of next year of its innovative diabetes treatment – Afrezza.
Keep Reading →
August 1 - News - Comments
This week's list of the most horrendous health-care stocks is brought to you by the letter "S." Just like on Sesame Street, all of the names we will discuss start with the same...
Keep Reading →
July 29 - News - Comments
Stock picking is both an art and a science. I first started investing in the pre-PC era when information was difficult for the average market player to access.
Keep Reading →
July 19 - Stock Analysis - Comments
I've come across this asset management firm on several occasions in recent months, as it has appeared on my screens regarding companies with share buybacks, strong free cash...
Keep Reading →
July 15 - Insider Trading - Comments
In today’s marketplace, there are many metrics investors can use to watch stocks. Two of the most under-the-radar are hedge fund and insider trading activity.
Keep Reading →
July 1 - News - Comments
In today’s marketplace, there are many indicators shareholders can use to watch the equity markets.
Keep Reading →
June 25 - News - Comments
If you'd ask most market participants, hedge funds are seen as slow, outdated investment vehicles of years past.
Keep Reading →
June 19 - News - Comments
SurModics, Inc. (NASDAQ:SRDX) was in 8 hedge funds' portfolio at the end of March.
Keep Reading →
June 14 - News - Comments
Is AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) the right pick for your portfolio? Prominent investors are taking a pessimistic view.
Keep Reading →
June 12 - News - Comments
IDEXX Laboratories, Inc. (NASDAQ:IDXX) was in 11 hedge funds' portfolio at the end of the first quarter of 2013.
Keep Reading →
June 10 - News - Comments
Late last year, Clovis Oncology Inc (NASDAQ:CLVS) saw its share price cut in half, to $11.50, after reporting that its Phase 3 drug CO-101 failed to show a benefit over chemotherapy...
Keep Reading →
June 10 - News - Comments
Every week at The Motley Fool we reflect on the top stories in the biotech sector in a wrap-up column.
Keep Reading →
June 10 - News - Comments
Many stocks encountered turbulence this week, but few were blown about like several biotech stocks.
Keep Reading →
June 10 - News - Comments
Let's start with Synta Pharmaceuticals Corp. (NASDAQ:SNTA).
Keep Reading →
June 10 - News - Comments
In the eyes of most investors, hedge funds are assumed to be underperforming, old financial vehicles of years past.
Keep Reading →
June 6 - News - Comments
Biotechnology stocks offer investors some of the highest potential for returns of any industry.
Keep Reading →
June 4 - News - Comments
Is Trinity Biotech plc (ADR) (NASDAQ:TRIB) a sound investment now? Hedge funds are reducing their bets on the stock.
Keep Reading →
April 18 - News - Comments
Is SurModics, Inc. (NASDAQ:SRDX) worth your attention right now? Hedge funds are in a pessimistic mood.
Keep Reading →
April 14 - News - Comments
In the 21st century investor’s toolkit, there are plenty of metrics shareholders can use to monitor their holdings.
Keep Reading →
April 11 - News - Comments
If you'd ask most stock holders, hedge funds are seen as slow, old financial vehicles of years past.
Keep Reading →
April 4 - News - Comments
As I noted five weeks ago, cancer statistics are both staggering and disappointing.
Keep Reading →
April 2 - News - Comments
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
March 15 - News - Comments